Cargando…

Cell-surface marker discovery for lung cancer

Lung cancer is the leading cause of cancer deaths in the United States. Novel lung cancer targeted therapeutic and molecular imaging agents are needed to improve outcomes and enable personalized care. Since these agents typically cannot cross the plasma membrane while carrying cytotoxic payload or i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Allison S., Khalil, Farah K., Welsh, Eric A., Schabath, Matthew B., Enkemann, Steven A., Davis, Andrea, Zhou, Jun-Min, Boulware, David C., Kim, Jongphil, Haura, Eric B., Morse, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768334/ https://www.ncbi.nlm.nih.gov/pubmed/29371917 http://dx.doi.org/10.18632/oncotarget.23009

Ejemplares similares

Cell-surface markers for colon adenoma and adenocarcinoma
por: Sewda, Kamini, et al.
Publicado: (2016)

A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma
por: Stewart, Paul A., et al.
Publicado: (2015)

A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma
por: Gray, Jhanelle E., et al.
Publicado: (2018)

Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
por: Gordian, Edna, et al.
Publicado: (2019)

Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
por: Gordian, Edna, et al.
Publicado: (2021)

Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma
por: Chen, Lu, et al.
Publicado: (2016)

Multi-Window CT Based Radiological Traits for Improving Early Detection in Lung Cancer Screening
por: Lu, Hong, et al.
Publicado: (2020)

Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer
por: Kim, Jae-Young, et al.
Publicado: (2016)

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
por: Schabath, Matthew B., et al.
Publicado: (2015)

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
por: Baldelli, Elisa, et al.
Publicado: (2015)

CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy
por: Li, Qian, et al.
Publicado: (2017)

Three Layers of Personalized Medicine in the Use of Sirolimus and Its Derivatives for the Treatment of Cancer
por: Delgado, Andres, et al.
Publicado: (2023)

Nicotine Promotes Tumor Growth and Metastasis in Mouse Models of Lung Cancer
por: Davis, Rebecca, et al.
Publicado: (2009)

Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
por: Machida, Kazuya, et al.
Publicado: (2010)

GMSimpute: a generalized two-step Lasso approach to impute missing values in label-free mass spectrum analysis
por: Li, Qian, et al.
Publicado: (2020)

A sequence-based identification of the genes detected by probesets on the Affymetrix U133 plus 2.0 array
por: Harbig, Jeremy, et al.
Publicado: (2005)

Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors
por: Balko, Justin M, et al.
Publicado: (2006)

Identical probes on different high-density oligonucleotide microarrays can produce different measurements of gene expression
por: Zhang, LanMin, et al.
Publicado: (2006)

Rapid SNP Discovery and Genetic Mapping Using Sequenced RAD Markers
por: Baird, Nathan A., et al.
Publicado: (2008)

Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer
por: Dhawan, Andrew, et al.
Publicado: (2017)

Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer
por: Ross, Karen E., et al.
Publicado: (2023)

Unsupervised discovery of ancestry-informative markers and genetic admixture proportions in biobank-scale datasets
por: Ko, Seyoon, et al.
Publicado: (2023)

Comprehensive phenotyping and biological marker discovery
por: Kantor, Aaron B.
Publicado: (2002)

Species-Specific Marker Discovery in Tilapia
por: Syaifudin, Mochamad, et al.
Publicado: (2019)

Translating Hispanic Genomic Factors in Lung Cancer Into Clinical Practice: EGFR Testing for Improved Outcomes
por: Hudson, Janella, et al.
Publicado: (2016)

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
por: Li, Jiannong, et al.
Publicado: (2010)

Transforming Growth Factor β Signaling Overcomes Dasatinib Resistance in Lung Cancer
por: Gordian, Edna, et al.
Publicado: (2014)

Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial
por: Schabath, Matthew B., et al.
Publicado: (2016)

Peritumoral and intratumoral radiomic features predict survival outcomes among patients diagnosed in lung cancer screening
por: Pérez-Morales, Jaileene, et al.
Publicado: (2020)

A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses
por: Boyle, Theresa A., et al.
Publicado: (2019)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
por: Creelan, Ben C., et al.
Publicado: (2019)

Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy
por: Kim, Eunjung, et al.
Publicado: (2018)

Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma
por: Schneeberger, Valentina E., et al.
Publicado: (2015)

Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells
por: Brazelle, William, et al.
Publicado: (2010)

Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone
por: Torrente, Laura, et al.
Publicado: (2020)

Next Generation Characterisation of Cereal Genomes for Marker Discovery
por: Visendi, Paul, et al.
Publicado: (2013)

Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance
por: Boyle, Theresa A., et al.
Publicado: (2020)

EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer
por: Singh, Sandeep, et al.
Publicado: (2012)

Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer
por: Chen, Dung-Tsa, et al.
Publicado: (2021)

Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS
por: Shin, Jihye, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p9i0aji5nfi9jivdoda2kajs6e